SCHEMBL19212441

SCHEMBL19212441

CC(C)CN(c1ccc(C2(C(=O)O)CCC2)cc1N)C1CCOCC1

nearest known ligand 0.43

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 12/20 0.43
PIK3CD O00329 2/20 0.38
APP P05067 1/20 0.36
ALDH1A1 P00352 1/20 0.34
LTB4R Q15722 2/20 0.34
LTB4R2 Q9NPC1 2/20 0.34
EZH2 Q15910 1/20 0.33
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19212373 0.98 IDO1 (0.41) IDO1PIK3CDAPPALDH1A1LTB4R
SCHEMBL19212386 0.91 IDO1 (0.42) IDO1LTB4RLTB4R2MEN1KMT2A
SCHEMBL19243701 0.90 IDO1 (0.38) IDO1PIK3CDEZH2MEN1KMT2A
SCHEMBL19212424 0.89 IDO1 (0.42) IDO1LTB4RLTB4R2MEN1KMT2A
SCHEMBL19243612 0.87 IDO1 (0.34) IDO1ALDH1A1LTB4RLTB4R2MEN1
SCHEMBL19212390 0.87 IDO1 (0.35) IDO1LTB4RLTB4R2MEN1KMT2A
SCHEMBL20601455 0.86 PIK3CD (0.36) IDO1PIK3CDAPPEZH2
SCHEMBL19243593 0.86 IDO1 (0.48) IDO1PIK3CDAPPALDH1A1EZH2
SCHEMBL19243672 0.84 IDO1 (0.46) IDO1PIK3CDAPPALDH1A1
SCHEMBL19243441 0.84 IDO1 (0.46) IDO1PIK3CDAPPALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11969425-B2 Inhibitor of indoleamine-2,3-dioxygenase (IDO) INVENTISBIO LLC (US) 2024-04-30 US disclosed
US-20230338373-A1 INHIBITOR OF INDOLEAMINE-2,3-DIOXYGENASE (IDO) INVENTISBIO LLC 2023-10-26 US disclosed
EP-3414224-B1 INHIBITOR OF INDOLEAMINE-2,3-DIOXYGENASE (IDO) INVENTISBIO LLC (US) 2022-03-23 EP disclosed
US-20220054486-A1 INHIBITOR OF INDOLEAMINE-2,3-DIOXYGENASE (IDO) INVENTISBIO LLC (US) 2022-02-24 US disclosed
US-10980807-B2 Inhibitor of indoleamine-2,3-dioxygenase (IDO) INVENTISBIO LLC (US) 2021-04-20 US disclosed
US-10980807-B2 Inhibitor of indoleamine-2,3-dioxygenase (IDO) INVENTISBIO LLC (US) 2021-04-20 US disclosed
US-20200046697-A1 INHIBITOR OF INDOLEAMINE-2,3-DIOXYGENASE (IDO) INVENTISBIO LLC 2020-02-13 US disclosed
US-20200046697-A1 INHIBITOR OF INDOLEAMINE-2,3-DIOXYGENASE (IDO) INVENTISBIO LLC 2020-02-13 US disclosed
EP-3414224-A1 INHIBITOR OF INDOLEAMINE-2,3-DIOXYGENASE (IDO) Inventisbio Inc. (KY) 2018-12-19 EP disclosed
WO-2017139414-A1 INHIBITOR OF INDOLEAMINE-2,3-DIOXYGENASE (IDO) INVENTISBIO INC. (KY) 2017-08-17 WO disclosed
WO-2017139414-A1 INHIBITOR OF INDOLEAMINE-2,3-DIOXYGENASE (IDO) INVENTISBIO INC. (KY) 2017-08-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230338373-A1 INHIBITOR OF INDOLEAMINE-2,3-DIOXYGENASE (IDO) IDO1, IDO2, INMT IDO1 1/4885PIK3CD 1600/4885APP 3855/4885
US-11969425-B2 Inhibitor of indoleamine-2,3-dioxygenase (IDO) IDO1, IDO2, INMT IDO1 1/4885PIK3CD 1600/4885APP 3855/4885
US-20220054486-A1 INHIBITOR OF INDOLEAMINE-2,3-DIOXYGENASE (IDO) IDO1, IDO2, INMT IDO1 1/4885PIK3CD 1600/4885APP 3855/4885
US-20200046697-A1 INHIBITOR OF INDOLEAMINE-2,3-DIOXYGENASE (IDO) IDO1, IDO2, INMT IDO1 1/4885PIK3CD 1600/4885APP 3855/4885
US-10980807-B2 Inhibitor of indoleamine-2,3-dioxygenase (IDO) IDO1, IDO2, INMT IDO1 1/4885PIK3CD 1600/4885APP 3855/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.